A Study To Evaluate The Safety And Tolerability Of PF-06342674 (RN168) In Subjects With Multiple Sclerosis (MS)

Status:	Terminated
Conditions:	Neurology, Neurology, Multiple Sclerosis
Therapuetic Areas:	Neurology, Other
Healthy:	No
Age Range:	18 - 55
Updated:	4/21/2016
Start Date:	September 2014
End Date:	October 2015

A Phase 1b, Double-Blinded, Placebo-Controlled, Randomized Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Multiple Ascending Doses Of Pf-06342674 (RN168) In Subjects With Multiple Sclerosis (MS)

PF-06342674 (RN168), being developed for the treatment of multiple sclerosis (MS), is an
antibody that binds to and inhibits the human interleukin-7 receptor, a component
potentially involved in MS. PF-06342674 (RN168) is expected to play a role in slowing down
the progression of the disease.

Inclusion Criteria:

- Women and men aged 18-55 yrs.

- Confirmed diagnosis of Multiple Sclerosis (MS) according to the 2010 revision of the
McDonald Criteria.

- Expanded Disability Status Scale (EDSS) between 0-5, inclusive.

Exclusion Criteria:

- Relapse episode of MS within 2 weeks of enrollment.

- Primary progressive MS without a relapsing component.

- Intolerant or unwilling to undergo MRI scanning. Treatment with disease modifying
agents up to 6 weeks prior to enrollment.

We found this trial at

sites

Pfizer Investigational Site

Cleveland, Ohio 44195

from

Cleveland, OH